Industries / Frontier science / Longevity
Rules
This work is how laws, regulators and the keepers of medical codes decide what may be sold or claimed for aging, and who checks it.
7
Milestones achieved, from 1977 to 2025.
2
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1977
Nevada licenses Gerovital
A 1977 Nevada law told the State Board of Health to license the manufacture in the state of Gerovital H3 (procaine hydrochloride with preservatives and stabilizers) and of laetrile, adding that "such licensing is not a representation that either substance has any therapeutic effect." At a state Senate hearing in May 1979, the only maker under the law, Rom-Amer Pharmaceuticals, said it had shipped about 600,000 capsules since 10 January 1979, and the state pharmacy board said the FDA opposed selling it without a prescription. The section is still in Nevada's statutes.
Lessona state can license a product's manufacture without saying it works, and this law said so in its text.
Credit
Nevada Legislature
1994
Supplements sold without review
The US Dietary Supplement Health and Education Act (DSHEA) let supplements carry statements about how an ingredient affects "the structure or function" of the body without FDA review. The maker must hold evidence that the statement is true, tell the FDA within 30 days, and print that it "has not been evaluated by the Food and Drug Administration" and that the product "is not intended to diagnose, treat, cure, or prevent any disease." The act also shuts out of supplements anything first approved as a drug, or first publicly studied as one, unless it was sold as a supplement or food before that.
Lessonunder this clause the order of events, not the evidence, decides whether an ingredient can be sold as a supplement.
Credit
US Congress
2022
Old age dropped from ICD-11
ICD-11 is the World Health Organization's (WHO) list of diagnosis codes, used on death certificates, in health statistics and for payment, and it took effect on 1 January 2022. WHO had proposed "old age" as the title of code MG2A, replacing "senility" from ICD-10, and an extra code, XT9T, that defined "ageing-related" in terms of "pathological processes". After campaigns by older people's groups, including Brazil's "Old Age is Not a Disease", and a meeting with WHO's ICD-11 committee in October 2021, WHO retitled MG2A "ageing associated decline in intrinsic capacity" and replaced "pathological" in XT9T with "biological".
Lessona code meant to focus health policy on the biology of aging was read by many as calling old age a disease.
Credit
WHO; the campaign as described by Kiran Rabheru, Julie Byles and Alexandre Kalache in The Lancet Healthy Longevity, June 2022
2024
China plans an anti-aging industry
On 11 January 2024 the General Office of China's State Council issued its opinion on developing the "silver economy", the economy serving older people (Guobanfa [2024] No. 1). Item 17, "develop the anti-aging industry", calls for research on skin aging, human aging models and hair health; for gene technology, regenerative medicine and laser and radio-frequency devices in anti-aging; and for genetic tests and molecular diagnostics that screen early for diseases of old age.
Credit
General Office of the State Council of the People's Republic of China
2024
A license for longevity clinics
On 31 October 2024 the Department of Health – Abu Dhabi, the emirate's health regulator, introduced a licensing framework and standards for "Healthy Longevity Medicine Centres", which it called the first of its kind in the world. The centers are to draw on patients' records in the emirate's health data exchange, Malaffi. On 19 November 2024 the department licensed the Institute for Healthier Living Abu Dhabi as the first such center.
Credit
Department of Health – Abu Dhabi
2025
NMN allowed back in supplements
Nicotinamide mononucleotide (NMN) is a molecule cells turn into NAD+, a coenzyme they need, and it is widely sold for longevity. In late 2022 the FDA said NMN could not be a supplement because it had been authorized for study as a drug, and withdrew its acknowledgement of one maker's NMN. After citizen petitions from the Natural Products Association (NPA), the Alliance for Natural Health USA and the Council for Responsible Nutrition (CRN), and a lawsuit by the NPA, the FDA reversed itself on 29 September 2025: NMN had been sold as a supplement in the US before any drug study was authorized. In December 2025 it restored that maker's notification. On 10 December 2025 Australia's Therapeutic Goods Administration (TGA) added NMN to the ingredients permitted in listed complementary medicines, the class that supplements are sold under there, with two years in which only the applicant, SyncoZymes of Shanghai, may use it.
Lessonthe FDA never disclosed the date of the drug authorization it had relied on, and CRN said that leaves companies with "a moving target".
nutritionaloutlook.comcirs-group.compolicycanary.ionutraingredients.com
Credit
FDA; NPA; TGA
2025
Montana licenses experimental clinics
In May 2025 Governor Greg Gianforte signed Montana Senate Bill 535, which the Alliance for Longevity Initiatives, the lobbying group that pushed it, calls the first state law to license experimental treatment centers. Licensed centers may sell drugs made in Montana that have passed phase I trials, the first small tests in people, which check safety but not whether a drug works. It builds on a 2023 law, SB 422, that opened Montana's Right to Try law, until then for the terminally ill, to all patients. Sharona Hoffman, a law and bioethics professor at Case Western Reserve University, told MIT Technology Review that selling drugs after phase I "could endanger patients".
Lessona law written to give dying patients a last option became a route for healthy people to reach unapproved longevity drugs.
Credit
Montana Legislature (State Senator Kenneth Bogner); Alliance for Longevity Initiatives
Watch for
Montana's first experimental centers
On 10 April 2026 Montana's Department of Public Health and Human Services proposed 25 rules to put SB 535 into effect (MAR Notice No. 2026-427.1). Each center must have a review board of at least four members, report adverse events to the department within five days and publish a yearly safety summary. Comments closed on 8 May 2026, and Longevity.Technology reported on 28 July 2026 that the rules were in place.
Achieved whenthe department lists a licensed center and that center publishes its first yearly review-board safety summary.
Claimed by
Montana Department of Public Health and Human Services, April 2026; Longevity.Technology, July 2026
An aging endpoint for FDA
An endpoint is the measure a trial uses to decide whether a drug worked. ARPA-H, the US Advanced Research Projects Agency for Health, announced on 24 February 2026 seven teams under its PROSPR program, with up to US$144 million over five years, to find early measures of healthy aging that trials can use. On 18 May 2026 a working group it convened sent the FDA a consensus statement on how "intrinsic capacity", a combined measure of movement, thinking, mood, the senses and vitality, could serve as an endpoint in healthspan trials.
Achieved whenthe FDA approves a drug on an intrinsic capacity endpoint, or one of its parts, or publishes guidance accepting it for aging trials.
Claimed by
ARPA-H and its working group, February and May 2026
Open
01
Longevity substances, country by country
An open, dated table of the legal status of the 25 substances most sold for longevity, such as NMN, nicotinamide riboside, rapamycin, metformin, spermidine, urolithin A, fisetin, DHEA, growth hormone and testosterone, in at least ten places (for example the US, the EU, the UK, Canada, Australia, Japan, China, Singapore, the UAE and India). Each cell says supplement or food, prescription only, not allowed, or pending, with a link to the regulator's own document and the date it was checked.
The briefCredit · unclaimed02
Anti-aging enforcement, counted
A public table of enforcement actions against anti-aging and longevity claims since 2001: FDA warning letters, Federal Trade Commission (FTC) cases, rulings of the UK Advertising Standards Authority, TGA infringement notices and Health Canada advisories. One row per action, with the product, the claim quoted, the legal basis, the outcome, and whether the product is still on sale.
The briefCredit · unclaimed
Open 01 · the brief
Longevity substances, country by country
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
An open, dated table of the legal status of the 25 substances most sold for longevity, such as NMN, nicotinamide riboside, rapamycin, metformin, spermidine, urolithin A, fisetin, DHEA, growth hormone and testosterone, in at least ten places (for example the US, the EU, the UK, Canada, Australia, Japan, China, Singapore, the UAE and India). Each cell says supplement or food, prescription only, not allowed, or pending, with a link to the regulator's own document and the date it was checked.
Why it is still open
Even for NMN alone, the summaries available come from vendors and consultancies and disagree. Australia changed its position on 10 December 2025 and the FDA in September 2025. CIRS Group, a regulatory consultancy, compared NMN in three markets on 31 December 2025, the US, Australia and the EU, where six novel-food applications were pending and none approved. Policy Canary tracks the US status of single ingredients as a paid service. No table across many countries and substances was found.
Built with what exists
Regulators' public databases (the EU Novel Food Catalogue, Australia's Permissible Ingredients Determination, Health Canada's Licensed Natural Health Products Database, the FDA's new dietary ingredient notifications, the database of Japan's Consumer Affairs Agency for Foods with Function Claims); an AI agent to fetch documents and draft entries with citations; a CSV file kept under version control.
First step
Fill the NMN row for all ten places from regulators' documents only, and note where they differ from vendor summaries.
Done looks like
250 cells (25 substances in 10 places), each with a link to a regulator's document and a date; a second person checks 20% of cells with at least 95% agreement; a change log updated every quarter.
Open 02 · the brief
Anti-aging enforcement, counted
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public table of enforcement actions against anti-aging and longevity claims since 2001: FDA warning letters, Federal Trade Commission (FTC) cases, rulings of the UK Advertising Standards Authority, TGA infringement notices and Health Canada advisories. One row per action, with the product, the claim quoted, the legal basis, the outcome, and whether the product is still on sale.
Why it is still open
In September 2001 the US General Accounting Office (now the Government Accountability Office) told the Senate Special Committee on Aging that it could find no recent, reliable estimate of the economic harm from unproven anti-aging products. It relied on an FTC review of 20 companies, which put average consumer losses at about US$1.8 million per company. No later count across agencies was found.
Built with what exists
The FDA's warning letter search, the FTC's case listings, the Advertising Standards Authority's rulings search and the TGA's published infringement notices; a classifier model such as Gemini Decision 1, which returns probabilities for up to 1,000 fixed-answer questions in one request (see the Note "A thousand questions, one pass"), checked against hand labels; a SQLite database.
First step
Download FDA warning letters from 2020 to 2026, filter them by keyword, and code the first 100 by hand.
Done looks like
Every FDA warning letter from 2015 to 2026 that mentions aging, anti-aging, longevity or lifespan, plus the matching actions of at least three other regulators, coded; the model's precision and recall measured on 300 hand-labeled letters and published.